Session (CTI)

Issue: HEOR provides the evidence needed to support affordability, value-based decision-making, and policy development, yet its strategic importance is still not consistently recognized. Traditional productivity metrics, such as publication counts or timelines, do not capture HEOR’s influence on payer strategy, evidence prioritization, policy engagement, or enterprise value. As policymakers and payers demand clearer demonstrations of value, HEOR’s inability to quantify its contributions has become a barrier to its credibility and relevance. The issue is understanding why HEOR’s impact remains difficult to measure and identifying practical approaches to clarify its role in policy, access, and value decisions. Overview: This 60-minute issue panel will debate the real-world challenges of demonstrating HEOR’s impact and explore contrasting viewpoints on how the field can strengthen its visibility with internal and external decision-makers. Three panelists representing biotech, midsize, and large HEOR organizations will present concise, distinct positions (10 minutes each). John will argue that HEOR undersells its influence and fails to measure the impact cross-functional partners already acknowledge. Kinga will contend that impact metrics should be grounded in how evidence is used in payer and policymaker interactions, supported by rapid feedback from integrated field teams. Jan will caution that global complexity, regional variation, and inconsistent data flows make unified HEOR impact metrics difficult to implement and potentially misleading. Moderated by AESARA—drawing on insights from its 2024 industry HEOR benchmarking initiative and its consulting experience in organizational transformation and evidence strategy—the session will begin by framing measurement gaps and opportunities for defining credible HEOR impact metrics. A 30-minute moderated debate and audience Q&A will challenge assumptions and surface practical solutions. HEOR stakeholders will leave with strategies to elevate HEOR’s visibility and better demonstrate its impact on policy, access, and enterprise decisions.